Tag Archive for: oncology

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

/in

Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]

Read more

Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025

/in

Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more…

Read more

Poolbeg Pharma plc – ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost

/in

Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres  25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

/in

Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies Financing led by Redmile Group and Blast, with participation […]

Read more
© Optimum Strategic Communications.